Yakira Capital Management’s SeaStar Medical ICU Stock Holding History

Yakira Capital Management’s Portfolio ICU Stock Details ICU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-804	Closed	-$2.07M	–	390
2022 Q3	$2.07M	Buy	+804	New	+$2.06M	0.3%	117

Other funds holding ICU

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

CCFM

Cohen & Co Financial Management New York $18.3M AUM 73.48% 1-Year Est. Return

SWA

SFMG Wealth Advisors Plano, Texas $1.48B AUM 15.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Yakira Capital Management's ICU Position: Q4 2022 in Review

Yakira Capital Management sold out of SeaStar Medical (ICU) in Q4 2022, closing a stake of 804 shares — an estimated $2.07M sold.

Yakira Capital Management first reported a position in ICU in Q3 2022 and held it in 1 quarter. The position peaked at $2.07M in Q3 2022. 8 funds tracked by Wall St. Rank hold ICU as of Q4 2022.

Yakira Capital Management reported no remaining SeaStar Medical position as of Q4 2022 after selling out during the quarter.
Yakira Capital Management sold 804 SeaStar Medical shares in Q4 2022, an estimated $2.07M.
Yakira Capital Management first reported a position in SeaStar Medical in Q3 2022 and held it in 1 quarter.
Yakira Capital Management's SeaStar Medical position peaked at $2.07M in Q3 2022.
8 funds tracked by Wall St. Rank held SeaStar Medical as of Q4 2022.

Based on Yakira Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.